Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$182.7MCash, Jun 2026
31moCash Runway (est.)
Follow IMRX by emailGet an email when IMRX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IMRX, unsubscribe in one click. Privacy
📣 What IMRX Says Is Next
mid-2028 · “In mid-2026, dosing the first patient in a pivotal Phase 3 clinical trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients (known as MAPKeeper 301), with a topline data readout expected in mid-2028.”
Company press release, Jun 1, 2026 · SEC filing
second half of the year · “Our Phase 2 lung cancer trial is on track to dose the first patient in the second half of the year.”
Company press release, May 15, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
IMRX reported $182.7M in cash and short-term investments (as of Jun 30, 2026) and used about $17.6M/quarter in operations, an estimated runway of 31.1 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.